GRI-0621

· GRI Bio Operations, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GRI-0621, covering 2025-10-30 to 2025-10-30. Get the full timeline:

Most recent: Clinical Trial Update: Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF [Phase 2]